Baxter International Inc.

Baxter Healthcare Sa

Baxalta Gmbh

Takeda Pharmaceutical Company Limited

Other

Birgit Maria Reipert

Hans-Peter Schwarz

Hartmut Ehrlich

Patrick Küry

Mantas Malisauskas

Hans-Peter Hartung

Christian Lubich

Nevena Tzekova

Corinna Hermann

Sebastian Bunk

Thomas Prenninger

Katharina Nora Steinitz

Paula Maria Wilhelmina Van Helden

Juergen Siekmann

Meinhard Hasslacher

Gerhard Antoine

Christa Mayer

Martin Feichtinger

Philipp M Bärnthaler

Julia Anzengruber

Maria Sasgary

Maria Schuster

Katarzyna Olas

Irina Elovaara

Patrick Kuery

The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.

Characterization of subvisible particles using a particle analyzer

The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.

Purification of factor VIII subspecies

The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.

IgG stimulated remyelination of peripheral nerves

The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.

FVIII peptides for immune tolerance induction and immunodiagnostics

The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.

Transgenic non-human animals expressing human blood clotting factors and uses thereof

The present invention relates to a cell-based in vitro screening assay for identifying and selecting therapeutic agents that inhibit amyloid &#x3b2;-induced cytotoxicity.

Anti-amyloid &#x3b2; activity of intravenous immunoglobulin (IVIG) in vitro

The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.

Detection of antibody that binds to water soluble polymer-modified polypeptides

The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.

IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease

Growing community of inventors

Vienna, Austria

Birgit Maria Reipert